Innovent and Shenogen Enter into a Collaboration to Evaluate the Combination of Tyvyt (sintilimab injection) + SNG1005 for Advanced Cancer

Innovent and Shenogen Enter into a Collaboration to Evaluate the Combination of Tyvyt (sintilimab injection) + SNG1005 for Advanced Cancer Innovent and Shenogen Enter into a Collaboration to Evaluate the Combination of Tyvyt (sintilimab injection) + SNG1005 for Advanced Cancer

Shots:

  • The companies enter into an agreement to evaluate the combination of Innovent’s Tyvyt with Shenogen’s SNG1005 for the patients with advanced cancer 
  • Shenogen has in-licensed SNG1005 and has exclusive rights to develop & commercialize it in Greater China. SNG1005 has completed multiple P-II trials in the US with an approved NMPA’s IND application of P-II/III for breast cancer carcinoma brain metastases
  • Tyvyt is an Ig-G4 mAb targeting PD-1, blocks PD-L1 pathway thus reactivates T-cells to kill cancer cells and has received NMPA’s approval for r/r cHL in Dec’18. SNG1005 is a first nab-paclitaxel therapeutic that binds to LRP1 and can penetrate the blood brain barrier

Click here to­ read full press release/ article | Ref: PRNewswire | Image: GMP News